glp-1 dosing schedule Dose-equivalence reference based on pivotal GLP-1/dual-agonist trials: SURMOUNT-1 (tirzepatide/Zepbound, 72 weeks) STEP-1 (subcutaneous semaglutide/Wegovy, 68 weeks) OASIS-4 (oral semaglutide/Wegovy, 64 weeks). For educational comparison only—these are The AFFORDABLE Flex-Dosing GLP-1/GIP Injection

In recent years, research has found that AOD 9604 is not limited to weight loss, but has comprehensive bone protection activities that promote bone formation, inhibit bone resorption, increase bone density, improve bone quality, repair joint cartilage, regulate calcium and phosphorus metabolism, and resist inflammation and oxidation

Researchers have speculated that perhaps amino acids play a role through physiological mechanisms to prompt animals to take in an adequate supply of protein

Challenges and Side Effects Despite their benefits, GLP-1 receptor agonists come with certain challenges: Gastrointestinal Issues: Nausea, vomiting, diarrhoea, and constipation are common side effects

Participants lost an average of ~12 lbs